±ØÍþÎ÷ººÄ·Áª¹ÙÍøÊ×Ò³

Ñз¢ÖÐÐļò½é

Introduction of R&D Center
¹«Ë¾Ò©ÎïÑз¢ÖÐÐÄÓÚ2003Ä꽨É裬 £¬£¬£¬£¬¼ç¸ºÑªÒºÖÆÆ·¡¢ÒßÃçµÈÐÂÒ©Ñз¢ÊÂÇ飬 £¬£¬£¬£¬ÏÖÔÚרְÑз¢¼°¹¤Òµ»¯ÊÖÒÕÖ°Ô±Ô¼70ÈË£¬ £¬£¬£¬£¬Ë¶Ê¿¼°²©Ê¿Ô¼30ÈË£¬ £¬£¬£¬£¬Ñз¢ÍŶÓÖ°Ô±½á¹¹ºÏÀí£¬ £¬£¬£¬£¬½¹µãÊÖÒÕÖ°Ô±¾ùΪÉúÎ﹤³Ì¡¢ÉúÎïÊÖÒÕ¡¢·Ö×ÓÉúÎïѧ¡¢ÃâÒßѧ¡¢Ò©Ñ§µÈÏà¹Ø×¨Òµ£¬ £¬£¬£¬£¬ÓªÒµÀíÂÛ»ù´¡Ôúʵ£¬ £¬£¬£¬£¬¾ßÓи»ºñµÄÑªÒºÖÆÆ·¡¢ÒßÃçÑз¢¼°¹¤Òµ»¯Êµ¼ùÂÄÀú ¡£¡£¡£¡£¡£¡£¡£¡£

±ðµÄ£¬ £¬£¬£¬£¬¹«Ë¾Ô¼ÇëÐÐÒµ¶¥¼â¿ÆÑ§¼ÒΪ¿Í×ùÑо¿Ö°Ô±¡¢ÊÖÒÕÕÕÁÏ£¬ £¬£¬£¬£¬²¢Ò»Ö±ÔöÇ¿ÓëÍⲿ¿ÆÑе¥Î»µÄÊÖÒÕºÏ×÷£¬ £¬£¬£¬£¬ÎªÑз¢Á¢ÒìÌṩÁËÓÐÁ¦µÄÈ˲Űü¹Ü ¡£¡£¡£¡£¡£¡£¡£¡£
BETWAY¡¤±ØÍþ(Î÷ººÄ·Áª)¹Ù·½ÍøÕ¾-West Ham United
¹«Ë¾ÓµÓС°¹ã¶«Ê¡ÂѰ×ÖÊ£¨¶àëÄ£©ÊèÉ¢´¿»¯¹¤³ÌÊÖÒÕÑо¿¿ª·¢ÖÐÐÄ¡±¡¢¡°¹ã¶«Ê¡ÔºÊ¿×¨¼ÒÆóÒµÊÂÇéÕ¾¡±¡¢¡°ÉîÛÚÊÐÑªÒºÖÆÆ·¹¤³ÌÊÖÒÕÑо¿¿ª·¢ÖÐÐÄ¡±¡¢¡°ÉîÛÚÊлùÒòÖØ×éÀàÁ¢ÒìÒ©Î﹤³ÌʵÑéÊÒ¡±¡¢¡°ÉîÛÚÊÐÂѰ×ÖÊ£¨¶àëÄ£©ÊèÉ¢´¿»¯¹«¹²ÊÖÒÕ·þÎñƽ̨¡±ÒÔ¼°¡°²©Ê¿ºóÁ¢Òìʵ¼ù»ùµØ¡±µÈ¶à¸öÑз¢Æ½Ì¨ ¡£¡£¡£¡£¡£¡£¡£¡£

Ñз¢´óÂ¥Å䱸Á˶๦Ч΢¿×°å¼ì²âϵͳ¡¢AKTA×Ô¶¯²ãÎö¹¤ÒÕÓÅ»¯ÏµÍ³¡¢Ó«¹â¶¨Á¿PCRÒÇ¡¢¸ßЧҺÏàÉ«Æ×ÒǵÈÑз¢¼°¼ì²âÆÊÎö×°±¸£¬ £¬£¬£¬£¬ÖÐÊÔÅäÌ×Ó²¼þÉèÊ©ÍêÉÆ£¬ £¬£¬£¬£¬×é³ÉÁËÇ¿ÓÐÁ¦µÄ¹«Ë¾ÊÖÒÕÁ¢ÒìÆ½Ì¨ ¡£¡£¡£¡£¡£¡£¡£¡£
BETWAY¡¤±ØÍþ(Î÷ººÄ·Áª)¹Ù·½ÍøÕ¾-West Ham United

Éú³¤ÍýÏë

development plan

¹«Ë¾Ç×½ü¹Ø×¢º£ÄÚÍâ×îпÆÑÐЧ¹ûºÍÏȽø¹¤ÒÕõè¾¶£¬ £¬£¬£¬£¬ÒÔÊг¡ºÍÕþ²ßΪµ¼Ïò£¬ £¬£¬£¬£¬ÒÔ×ÔÉíϵͳÄÜÁ¦ÎªÒÀÍУ¬ £¬£¬£¬£¬ÆÕ±é¶Ô½Óº£ÄÚ¡¢¹ú¼Ê¿ÆÑÐÔºËùºÍÁ¢ÒìÑз¢ÆóÒµ£¬ £¬£¬£¬£¬ÒÔ²úÆ·ÊÖÒÕÁ¢ÒìÎªÍ»ÆÆ£¬ £¬£¬£¬£¬Ò»Á¬×öÇ¿ÑªÒºÖÆÆ·»ùʯӪҵ£¬ £¬£¬£¬£¬ÆðÔ´Ðγɹ«Ë¾²úÆ·²î±ð»¯¾ºÕùÓÅÊÆ£»£»£»£»£»£»£»Í¬Ê±£¬ £¬£¬£¬£¬ÒÔǰÆÚÒßÃçÏîÄ¿Ñо¿Îª»ù´ ¡£¡£¡£¡£¡£¡£¡£¡£¬ £¬£¬£¬£¬¼ÓËٽṹÐÂÐÍÒßÃçÊÖÒÕÆ½Ì¨£¬ £¬£¬£¬£¬ÅàÓýǰհÐÔ¹¤ÒµÏîÄ¿£¬ £¬£¬£¬£¬ÐγÉÒÔ×ÔÖ÷¿ª·¢ÎªÖ÷£¬ £¬£¬£¬£¬ÍŽáÑз¢Îª¸¨µÄÕûºÏʽÑз¢Ä£Ê½ ¡£¡£¡£¡£¡£¡£¡£¡£

¡°Ê®ËÄÎ塱£¨2021-2025Ä꣩ÐÂÕ½ÂÔÆÚÄÚ£¬ £¬£¬£¬£¬±ØÍþÎ÷ººÄ·Áª¹ÙÍøÊ×Ò³ÉúÎォÃé׼ȫÇòÉúÎïÒ½Ò©¹¤ÒµµÄÁ¢ÒìÖÆ¸ßµãºÍÏȽøÄ£Ê½£¬ £¬£¬£¬£¬Ë³Ó¦¹¤ÒµÇ÷ÊÆ£¬ £¬£¬£¬£¬ÈÚÈëÇøÓòÉú³¤£¬ £¬£¬£¬£¬¼æ¹Ë¡°¹æÄ£ÓëÀûÈó¡¢ËÙÂÊÓëÖÊÁ¿¡¢¶ÌÆÚÓëºã¾Ã¡±Èý¶Ôƽºâ£¬ £¬£¬£¬£¬ÊµÏÖÑªÒºÖÆÆ·ÓëÉúÎïÒ½Ò©¡°Ë«¹ì¡±²¢½ø ¡£¡£¡£¡£¡£¡£¡£¡£

BETWAY¡¤±ØÍþ(Î÷ººÄ·Áª)¹Ù·½ÍøÕ¾-West Ham United

Á¢ÒìЧ¹û

INNOVATIVE ACHIEVEMENTS
ΪÃãÀøÖ§³ÖÑз¢Á¢Ò죬 £¬£¬£¬£¬½üÎåÄ깫˾Ñз¢×ÜͶÈ볬Á½ÒÚÔª£¬ £¬£¬£¬£¬²¢Öƶ©ÁË¡¶¿ÆÑ§Á¢Òì½±Àø²½·¥¡·¡¢¡¶¶ÔÍâ¿Æ¼¼Ð§¹ûת»¯ÏîÄ¿½±Àø²½·¥£¨ÊÔÐУ©¡·µÈϵÁм¤ÀøÖƶȣ¬ £¬£¬£¬£¬Ìá¸ßÁËÑз¢ÊÖÒÕÖ°Ô±Á¢Òì»îÁ¦ ¡£¡£¡£¡£¡£¡£¡£¡£¹«Ë¾ÄÚ²¿°´ÆÚ¿ªÕ¹¡°¿Æ¼¼Á¢ÒìÔ˶¯¡±£¬ £¬£¬£¬£¬³ä·ÖÑéÕ¹Ô±¹¤×ÔÖ÷Äܶ¯ÐÔ£¬ £¬£¬£¬£¬´î½¨Õ¹Ê¾ÍŶӼ°Ð¡ÎÒ˽¼ÒÁ¢ÒìÄÜÁ¦µÄÎę̀£¬ £¬£¬£¬£¬ÐγÉÓÅÒìµÄÁ¢ÒìÆø·Õ ¡£¡£¡£¡£¡£¡£¡£¡£

×èÖ¹ÏÖÔÚ£¬ £¬£¬£¬£¬

¹«Ë¾½ÒÏþÆÚ¿¯ÂÛÎļ°¾Û»áÂÛÎÄ100ÓàÆª£¬ £¬£¬£¬£¬

ÆäÖÐSCIÎÄÕÂ12ƪ ¡£¡£¡£¡£¡£¡£¡£¡£

ÒÑÓµÓÐרÀû70Ï £¬£¬£¬£¬

ÆäÖз¢Ã÷רÀû28Ï £¬£¬£¬£¬

ÊÊÓÃÐÂÐÍרÀû42Ïî ¡£¡£¡£¡£¡£¡£¡£¡£

ÒÑ»ñ·¢Ã÷רÀû

ÐòºÅÃû³Æ
1¾²Âö×¢ÉäÓÃÈËÒÒÐ͸ÎÑ×ÃâÒßÇòÂѰ׵ÄÖÆ±¸ÒªÁì
2Ò»ÖÖ´ü×°±ùѪ½¬×Ô¶¯·Ö¼ð»ú
3È˾Þϸ°û²¡¶¾IgG¿¹Ìå¼ì²âÊÔ¼ÁºÐºÍ¼ì²âÒªÁì
4¾²×¢¾Þϸ°û²¡¶¾ÈËÃâÒßÇòÂѰ׼°ÆäÖÆ±¸ÒªÁì
5¿ñÈ®²¡²¡¶¾CTN¼¦Åßϸ°û˳ӦÖê
6¿ñÈ®²¡²¡¶¾CTN-1Öê¶ÔÔ­´ú¼¦Åß³ÉÏËάϸ°ûµÄ˳ӦҪÁì
7Ò»ÖÖ¾²×¢ÈËÃâÒßÇòÂѰ׵ÄÖÆ±¸ÒªÁì
8Ò»ÖÖµ¥×é·ÖTMBÏÔɫҺ¼°ÆäÖÆ±¸ÒªÁì
9Ò»ÖÖµ¥×é·ÖTMBÏÔɫҺµÄÖÕÖ¹Òº¼°ÆäÖÆ±¸ÒªÁì
10Ò»ÖÖ´Ó×é·ÖIV-2³ÁµíÖÐÌáÈ¡ÈËѪ°×ÂѰ׵ÄÒªÁì
11Ò»ÖÖÈËѪ½¬ÔØÖ¬ÂѰ×A#IµÄÊèÉ¢´¿»¯ÒªÁì
12Ò»ÖÖÈËѪ½¬ÂѰצÁ1#¿¹ÒÈÂѰ×øµÄÊèÉ¢´¿»¯ÒªÁì
13Ò»ÖÖÖÊÁ£DNAµÄ¹¤Òµ»¯´¿»¯ÒªÁì¼°ÖÊÁ£DNA
14¾²×¢ÐÂÐ͹Ú×´²¡¶¾ÈËÃâÒßÇòÂѰ׵ÄÖÆ±¸ÒªÁì
15Ò»ÖÖÖÊÁ£DNAÔ­ÒºÖÆ±¸ÒªÁì
16Ò»ÖÖ¼¦Åßϸ°û¿ñÈ®²¡²¡¶¾µÄÉúÎï·´Ó¦Æ÷¹¤ÒÕ
17Ò»ÖÖ¿ñÈ®²¡ÒßÃçÃð»îÑéÖ¤µÄÊÔÑéÒªÁì
18Ò»ÖÖÁ÷¸Ð²¡¶¾ÁѽâÒßÃçÔ­ÒºµÄÖÆ±¸ÒªÁì
19Ò»ÖÖÁ÷¸Ð²¡¶¾ÒßÃçѪÄýËØº¬Á¿²â¶¨ÒªÁì¼°ÊÔ¼ÁºÐ
20ËļÛÁ÷¸Ð²¡¶¾ÁÏÒºÖÆ±¸ÒªÁì¡¢ËļÛÁ÷¸Ð²¡¶¾ÁѽâÒßÃç¼°ÆäÖÆ±¸ÒªÁì
21Ò»ÖÖ¼¦Åßϸ°ûµÄ¼ÆÊýÒªÁì
22Ò»ÖÖÄýѪÒò×ÓVII½Ø¶ÌÌå¼°ÆäÖÆ±¸ÒªÁìºÍÓ¦ÓÃ
23Ò»ÖÖÖØ×éÈËÏËÈÜøԭ¼°ÆäÖÆ±¸ÒªÁìºÍÓ¦ÓÃ
24Ò»ÖÖ¿¹A¡¢¿¹BѪÄýËØµÎ¶È²â¶¨ÒªÁì
25Ò»ÖÖÖØ×éÈËÏËÁ¬ÂѰ׶³¸Éº£Ã༰ÆäÖÆ±¸ÒªÁì
26Ò»ÖÖÌá¸ßË®¶»¼õ¶¾»îÒßÃ粡¶¾²úÁ¿µÄÖÆ±¸ÒªÁì
27Ò»ÖÖÖØ×éÏËÁ¬ÈÚºÏÂѰ׼°ÆäÓ¦ÓÃ
28Ò»ÖÖÖØ×éÈËÏËÁ¬ÂѰ׼°ÆäÖÆ±¸ÒªÁìºÍÓ¦ÓÃ
29Ò»ÖÖ³µ¼äÓðáÔË»úеÈË
30Ò»ÖÖ×¢ÉäÓÃË®±£ÎÂ×°ÖÃ
31Ò»ÖÖ½¬´üÓàÒº½ÓÄÉ×°ÖÃ
32Ò»ÖÖÎÞ¾úÇø³ý¾ú¹ýÂËÅÅÆø×°ÖÃ
33Ò»ÖÖ±íÀäÆ÷³ý˪װÖÃ
34Ò»ÖÖÖÆÒ©ÓÃÐýѹ²»Ðâ¸Ö¿ò¼Ü
35Ò»ÖÖ½¬´üÏ´åª×°ÖÃ
36Ò»ÖÖÔ­´úϸ°ûÎÞ¾ú×Ô¶¯×àÀÖÆ÷
37Ò»ÖÖÄý½ºÓýÁ°èÖù
38Ò»ÖÖÐÂÐ͵ĹܵÀ¼õÕñ×°ÖÃ
39Ò»ÖÖÐÂÐ͵Ä×ÔÁ¦¿Õµ÷¾»»¯ÏµÍ³
40Ò»ÖÖºãκãʪµÄ¿Õµ÷¾»»¯ÏµÍ³
41Ò»ÖÖµÍÎÂÀä¿âÕô·¢Æ÷¼°Æä³ý±ù×°ÖÃ
42Ò»ÖֿɱÜÃâ±Ã³éÏеIJ¹Ë®ÏµÍ³
43Ò»ÖÖÐÂÐ͵ÄÎÛÄà¸É»¯×°±¸
44Ò»ÖÖ·ÏË®ÍøÂç¼°µ¼Á÷×°ÖÃ
45Ò»ÖÖÊÊÓÃÓÚµÍÎÂÇéÐεÄÖ§³Ð×°ÖÃ
46Ò»ÖÖÐÂÐÍÖùÈû±ÃÃð¾ú×°ÖÃ
47Ò»ÖÖÐÂÐͳý¾ú¹ýÂË×°ÖÃ
48Ò»ÖÖÐÂÐ;߱¸»ØÂ˹¦Ð§µÄ³ý¾ú¹ýÂË×°ÖÃ
49Ò»ÖÖ´¦Öóͷ£ÄýѪÒò×ÓÀà³ÁµíµÄÈ«×Ô¶¯ÇÐÁ£»£»£»£»£»£»£»ú
50Ò»ÖÖÐÂÐ͵ĻýË®ÍøÂç×°ÖÃ
51Ò»ÖÖÕôÆûÈÈÄܽÓÄÉ×°ÖÃ
52Ò»ÖÖÐÂÐ͵Ä×¢ÉäÓÃË®½ÓÄÉ×°ÖÃ
53Ò»ÖÖÒÆ¶¯Ê½Ë®²Û
54Ò»ÖÖÐÂÐÍѹ²î¼ì²âºãѹװÖÃ
55Ò»ÖÖ·À¹à×°Õë¹ÜÍ»³ö×°ÖÃ
56Ò»ÖÖÉÁÕôÆû·ÏË®Ïû¶¾ÏµÍ³
57Ò»ÖÖÉÁÕôÆû¾Ö²¿¿Õ¼ä¼ÓÈÈϵͳ
58Ò»ÖÖ×éºÏ¹ýÂË×Ô¶¯ÊÂÇéÕ¾
59Ò»ÖÖ³ÁµíÍøÂç×À
60Ò»ÖÖѪ½¬´üÄÚ²ÐÁôѪ½¬µÄÍøÂç×°ÖÃ
61Ò»Öֿɵ÷ÀíµÄÒºµªÖü´æÍ°
62Ò»ÖÖÖÆÆ·½ÓÄÉ×°ÖÃ
63Ò»ÖÖÇݵ°½ÓÖÖÊÕ»ñÒ»Ìå»ú
64Ò»ÖÖÇݵ°Ï¸°ûÌáÈ¡ÓÃÔ­Òº×àÀÖ×°ÖÃ
65Ò»ÖÖÓÃÓÚÉúÎï·´Ó¦Æ÷Í¨Æø×°ÖÃ
66Ò»ÖÖÐÂÐÍÒÆ¶¯Ê½Èí¹ÜÊÕÄɼÜ
67Ò»ÖÖ¼ÓÒ©×°ÖÃ
68Ò»ÖÖÐÂÐÍ×Ô¶¯´µÉ¨ÅÅÎÛ×°ÖÃ
69Ò»ÖÖÐÂÐ굀 CIP ¼îÒº½ÓÄÉ×°ÖÃ
70Ò»ÖÖÀäý½µÎÂ×°ÖÃ

ÒѽÒÏþSCIÂÛÎÄ

ÐòºÅÃû³Æ
1Liao Mingfeng,Liao Xuejiao,Yuan Jing,Zhou Bing,Liu Yang,Jiang Xiao,Zhang Zhan,Guo Caiping,Zhang Yunjia,Zhang Shuye,Liu Lei,Zhang Zheng. The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID©\19[J]. Clinical and Translational Medicine,2021,11(11):
2Ji Qianqian,Guo Caiping,Xie Chen,Wu Yingdan,Zhang Pei,Li Hui,Lu Yongjun. Correction to: Genetically engineered cell lines for ¦Á1-antitrypsin expression.[J]. Biotechnology letters,2018,40(9-10):
3Ji Qianqian,Guo Caiping,Xie Chen,Wu Yingdan,Zhang Pei,Li Hui,Lu Yongjun. Genetically engineered cell lines for ¦Á1-antitrypsin expression.[J]. Biotechnology letters,2017,39(10):
4Shimao Zhu,Caiping Guo. Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential[J]. Viruses,2016,8(11):
5Caiping Guo(Corresponding author), Chunhua Wang, Shan Luo, Shimao Zhu, Hui Li, Yongdi Liu, Lanzhen Zhou, Pei Zhang, Xin Zhang, Yujiang Ding, Weirong Huang, Kaiyong Wu, Yanpeng Zhang, Weihua Rong, Hua Tian; The adaptation of a CTN-1 rabies virus strain to high-titered growth in chick embryo cells for vaccine development; Virology Journal 2014, 11£¨85£©£¬ £¬£¬£¬£¬http://www.virologyj.com/content/11/1/85, (SCI, IF: 2.092).
6Caiping Guo, Kewein Liu, Haibo Luo, Hongbo Chen, Yi Zheng, Shengnan Sun, Qian Zhang, Laiqiang Huang. Potent Anti-tumor Effect Generated by a Novel Human Papillomavirus (HPV) Antagonist Peptide Reactivating the pRb/E2F Pathway. PLoS One. 2011; 6(3): e17734. (SCI, IF: 4.351)
7Caiping Guo, Kewein Liu, Yi Zheng, Haibo Luo, Hongbo Chen, Laiqiang Huang. Apoptosis Induced by an Antagonist Peptide against HPV16 E7 in Vitro and in Vivo via Restoration of p53. Apoptosis. 2011; 16(6): 606-618; (SCI, IF: 4.066).
8Hongbo Chen, Xiaomeng Shen, Caiping Guo, Hujun Zhu, Langzhen Zhou, Yongqiang Zhu, Hao Wang, Yi Zheng, Laiqiong Huang. Phosphatase and tensin homolog reconstruction and vascular endothelial growth factor knockdown synergistically inhibit the growth of glioblastoma. Cancer Biother Radiopharm. 2010; 25 (6): 713-21. (SCI, IF: 1.443)
9Hongbo Chen, Lin Mei, Langzhen Zhou, Xudong Zhang, Caiping Guo, J Li, Hao Wang, Yongqiang Zhu, Yi Zheng, Laiqiang Huang. Moesin-ezrin-radixin-like protein (merlin) mediates protein interacting with the carboxyl terminus-1 (PICT-1)-induced growth inhibition of glioblastoma cells in the nucleus. Int J Biochem Cell Biol. 2011; 43 (4): 545-55. (SCI, IF: 4.887)
10Hongbo Chen, Ling Mei, Langzhen Zhou, Xiaomeng Shen, Caiping Guo, Yi Zheng, Huijun Zhu, Yongqiang Zhu, L Huang. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol. 2010. £¨SCI, IF: 2.903£©
11Zhan Zhang , Yiwu Xie, Jilin Hong, Xing Zhang.? SARSIg Group. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion. 2005 Jul;45(7):1160-4.£¨SCI, IF:3.526£©
12¡¶Efficient production of recombinant human FVII in CHO cells using the piggyBac transposon system¡·£¨×÷ÕߣºZhen Yang , Xueyun Wang, Shan Luo , Hui Li, Jiangbo Xu, Linlin Liang , Zhimin He , Guangyuan Wang, Zhuobin Wu , Nan Zhong, Haijun Xiang, Zhan Zhang, Caiping Guo, Yunjia Zhang, Fei Yan£©£¬ £¬£¬£¬£¬ÆÚ¿¯£ºProtein Expression and Puriffcation
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿